MA29404B1 - Preparation pharmaceutique - Google Patents

Preparation pharmaceutique

Info

Publication number
MA29404B1
MA29404B1 MA30318A MA30318A MA29404B1 MA 29404 B1 MA29404 B1 MA 29404B1 MA 30318 A MA30318 A MA 30318A MA 30318 A MA30318 A MA 30318A MA 29404 B1 MA29404 B1 MA 29404B1
Authority
MA
Morocco
Prior art keywords
pharmaceutical preparation
aberrational
pkt
activity
treatment
Prior art date
Application number
MA30318A
Other languages
English (en)
Inventor
Barry Howard Carter
Dwayne A Campbell
Original Assignee
Smithkline Beecham Cork Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37115487&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29404(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Cork Ltd filed Critical Smithkline Beecham Cork Ltd
Publication of MA29404B1 publication Critical patent/MA29404B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'INVENTION PORTE SUR UNE PRÉPARATION PHARMACEUTIQUE ORALE CONTENANT DES SELS DITOSYLATE DE 4-QUINAZOLINEAMINES ET SUR LEURS MÉTHODES D'UTILISATION POUR LE TRAITEMENT DE TROUBLES CARACTÉRISÉS PAR UNE ACTIVITÉ ABERRANTE DE LA PKT DE LA FAMILLE ERBB.
MA30318A 2005-04-19 2007-10-25 Preparation pharmaceutique MA29404B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67280505P 2005-04-19 2005-04-19

Publications (1)

Publication Number Publication Date
MA29404B1 true MA29404B1 (fr) 2008-04-01

Family

ID=37115487

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30318A MA29404B1 (fr) 2005-04-19 2007-10-25 Preparation pharmaceutique

Country Status (28)

Country Link
US (3) US8821927B2 (fr)
EP (1) EP1871347B1 (fr)
JP (1) JP5202302B2 (fr)
KR (1) KR101356748B1 (fr)
CN (1) CN101203211B (fr)
AR (1) AR054252A1 (fr)
AU (1) AU2006236423B2 (fr)
BR (1) BRPI0609962B1 (fr)
CA (1) CA2606207C (fr)
CY (1) CY1118179T1 (fr)
DK (1) DK1871347T3 (fr)
EA (1) EA200702253A1 (fr)
ES (1) ES2601503T3 (fr)
HR (1) HRP20161429T1 (fr)
HU (1) HUE030982T2 (fr)
IL (1) IL186336A0 (fr)
LT (1) LT1871347T (fr)
MA (1) MA29404B1 (fr)
MX (1) MX2007013089A (fr)
NO (1) NO20075111L (fr)
NZ (1) NZ562223A (fr)
PE (1) PE20061430A1 (fr)
PL (1) PL1871347T3 (fr)
PT (1) PT1871347T (fr)
SI (1) SI1871347T1 (fr)
TW (1) TW200716204A (fr)
WO (1) WO2006113649A1 (fr)
ZA (1) ZA200708705B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0609962B1 (pt) * 2005-04-19 2022-01-18 Novartis Ag Composição farmacêutica oral
WO2009137714A2 (fr) * 2008-05-07 2009-11-12 Teva Pharmaceutical Industries Ltd. Formes de ditosylate de lapatinib et procédés pour leur préparation
EP2158912A1 (fr) 2008-08-25 2010-03-03 Ratiopharm GmbH Composition pharmaceutique comportant de la N-[3-chhloro-4-[3-fluorophenyl)methoxy)phenyl]6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
EP2158913A1 (fr) 2008-08-25 2010-03-03 Ratiopharm GmbH Composition pharmaceutique comportant de la N-[3-chhloro-4-[3-fluorophenyl)methoxy)phenyl]6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
WO2010099150A1 (fr) * 2009-02-24 2010-09-02 Smithkline Beecham (Cork) Limited Comprimé pharmaceutique et procédé
US20120245351A1 (en) * 2009-09-29 2012-09-27 Natco Pharma Limited Process for the preparation of lapatinib and its pharmaceutically acceptable salts
ES2530755T3 (es) 2010-05-21 2015-03-05 Glaxosmithkline Llc Terapia de combinación para el tratamiento del cáncer
US20130072507A1 (en) 2010-05-21 2013-03-21 Glaxosmithkline Llc Combination
CN103269692B (zh) 2010-08-03 2018-02-23 韦利塞普特治疗有限公司 用于治疗膀胱过度活动症的β‑3肾上腺素能受体激动剂和毒蕈碱性受体拮抗剂的药物组合
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
ES2635620T3 (es) * 2013-02-19 2017-10-04 Hexal Ag Composición farmacéutica que comprende n-[3-cloro-4-(3-fluorobenciloxi)fenil]-6-[5({[2-(metilsulfonil)etil]amino} metil)-2-furil]quinazolin-4-amina o una sal, solvato o sal solvatada farmacéuticamente aceptables de la misma
WO2014170910A1 (fr) 2013-04-04 2014-10-23 Natco Pharma Limited Procédé de préparation du lapatinib
US9636340B2 (en) 2013-11-12 2017-05-02 Ayyappan K. Rajasekaran Kinase inhibitors
CN107205964A (zh) 2014-12-03 2017-09-26 威力塞帕特治疗股份有限公司 使用调节释放索拉贝隆用于下尿路症状的组合物和方法
CN106389373B (zh) * 2015-07-29 2019-07-02 四川科伦药物研究院有限公司 一种二甲苯磺酸拉帕替尼片剂及其制备方法
CN106511289A (zh) * 2015-09-10 2017-03-22 湖北生物医药产业技术研究院有限公司 甲苯磺酸拉帕替尼片剂及其制备方法
US10065922B2 (en) 2015-10-23 2018-09-04 Velicept Therapeutics, Inc. Solabegron zwitterion and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506248A (en) * 1993-08-02 1996-04-09 Bristol-Myers Squibb Company Pharmaceutical compositions having good dissolution properties
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
NZ336233A (en) 1997-04-25 2001-01-26 Janssen Pharmaceutica Nv Phenyl substituted quinazolines on 4-position and 2-quinazolinone moiety bearing a carbon or nitrogen-linked imidazolyl moiety
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
BR0111947A (pt) 2000-06-30 2003-05-06 Glaxo Group Ltd Composto, composição farmacêutica, método para o tratamento de um distúrbio em um mamìfero, uso de um composto e processo para preparar, um composto
JP4458746B2 (ja) 2001-01-16 2010-04-28 グラクソ グループ リミテッド 癌の治療方法
EP1492568A1 (fr) 2002-04-08 2005-01-05 SmithKline Beecham Corporation Methode de traitement du cancer consistant a administrer un inhibiteur de la famille erb et un inhibiteur de raf et/ou de ras
WO2004000094A2 (fr) 2002-06-19 2003-12-31 Smithkline Beecham Corporation Marqueurs predictifs utilises dans le traitement du cancer
BRPI0609962B1 (pt) * 2005-04-19 2022-01-18 Novartis Ag Composição farmacêutica oral

Also Published As

Publication number Publication date
US20140335177A1 (en) 2014-11-13
HRP20161429T1 (hr) 2016-12-16
CY1118179T1 (el) 2017-06-28
EP1871347A4 (fr) 2012-10-31
ES2601503T3 (es) 2017-02-15
CA2606207A1 (fr) 2006-10-26
DK1871347T3 (en) 2016-11-28
EA200702253A1 (ru) 2008-04-28
US20080206330A1 (en) 2008-08-28
ZA200708705B (en) 2009-12-30
NO20075111L (no) 2007-11-16
NZ562223A (en) 2010-01-29
US8821927B2 (en) 2014-09-02
PL1871347T3 (pl) 2017-04-28
JP5202302B2 (ja) 2013-06-05
WO2006113649A1 (fr) 2006-10-26
CN101203211A (zh) 2008-06-18
PT1871347T (pt) 2016-11-10
KR101356748B1 (ko) 2014-02-06
BRPI0609962B1 (pt) 2022-01-18
IL186336A0 (en) 2008-01-20
EP1871347A1 (fr) 2008-01-02
AU2006236423A1 (en) 2006-10-26
KR20080005557A (ko) 2008-01-14
HUE030982T2 (en) 2017-06-28
EP1871347B1 (fr) 2016-08-03
CN101203211B (zh) 2012-08-08
LT1871347T (lt) 2016-11-10
TW200716204A (en) 2007-05-01
US20160143909A1 (en) 2016-05-26
CA2606207C (fr) 2014-11-18
SI1871347T1 (sl) 2016-11-30
BRPI0609962A2 (pt) 2011-10-11
MX2007013089A (es) 2008-01-14
AR054252A1 (es) 2007-06-13
JP2008536931A (ja) 2008-09-11
PE20061430A1 (es) 2007-01-25
AU2006236423B2 (en) 2009-12-10

Similar Documents

Publication Publication Date Title
MA29404B1 (fr) Preparation pharmaceutique
MA31764B1 (fr) Composés et compositions en tant que modulateurs de l'activité de gpr119
MA27596A1 (fr) Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation
MA30324B1 (fr) Benzimidazoles presentant une activite au niveau du recepteur m1 et leurs utilisations en medecine.
MA47447A (fr) 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer
TNSN07021A1 (fr) Derives de quinazoline -4-yl-piperidine et cinnoline -4-yl-piperidine servant d'inhibiteurs de pde10 pour le traitement de troubles du snc
MEP45308A (en) [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
MA31373B1 (fr) Composes amino-heterocycliques
MA27448A1 (fr) Derives de pyridine modulateurs du recepteur cb2
MA27438A1 (fr) Piperazines heterocycliques substituees pour le traitement de la schizophrenie
TNSN04156A1 (fr) Pyridinones substituees servant de modulateurs de la map-kinase p38
MA30339B1 (fr) Azolopyrimidines inhibitrices de l'activite du recepteur cannabinoïde 1
MA27568A1 (fr) Derives de pyrrolopyrimidine
TNSN07063A1 (fr) Utilisations therapeutiques d'inhibiteurs de rtp801
MA33053B1 (fr) Inhibiteurs de la poly(adp-ribose) polymerase (parp)
MA34474B1 (fr) Agonistes de gpr40
TNSN03130A1 (fr) Inhibiteurs de protease du vih, compositions les contenant, leurs utilisations pharmaceutiques et matieres pour leur synthese
EA200700035A1 (ru) Сульфаматные и сульфамидные производные для лечения эпилепсии и родственных di sorders
MA30089B1 (fr) (arylsulfonyl)-pyrasolopiperidines
MA27661A1 (fr) Indolone-oxazolidinones antibacteriennes, intermediaires pour leur preparation et compositions pharmaceutiques les contenant
BRPI0414864A (pt) composição farmacêutica multiparticulada compreendendo ácido micofenólico ou micofenolato de sódio e combinação com rapamicida
MA46229B1 (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
EA200701856A1 (ru) Тетрагидропиридоазепин-8-оны и родственные соединения для лечения шизофрении
DE60024857D1 (de) Neue verbindungen
DE602006009556D1 (de) Chinolin-derivate zur behandlung von mglur5-rezeptor-vermittelten erkrankungen